Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Shire targets Allergan's dry-eye market share by pricing Xiidra at $5K per year--right on par with Restasis
Shire targets Allergan's dry-eye market share by pricing Xiidra at $5K per year--right on par with Restasis
Shire targets Allergan's dry-eye market share by pricing Xiidra at $5K per year--right on par with Restasis
Submitted by
admin
on July 26, 2016 - 11:25am
Source:
Fierce Pharma
News Tags:
dry eye disease
Shire
Allergan
Xiidra
Restasis
Headline:
Shire targets Allergan's dry-eye market share by pricing Xiidra at $5K per year--right on par with Restasis
Do Not Allow Advertisers to Use My Personal information
